LSE:AVCT (Avacta Group Plc)
About AVCT
Avacta is an early-stage biotech firm specialising in the fields of diagnostics and therapeutics. Its diagnostics division created a proprietary platform called Affimer. It consists of a portfolio of reagent proteins that can be used to detect specific infections within a given sample. Traditionally this process is achieved using antibodies. However, manufacturing antibodies is a complex, time-consuming process that Affimer reagents don’t have to go through.
In 2020, Avacta leveraged its Affimer platform to create Covid-19 lateral flow tests. This was the catalyst behind the AVCT share price spike that year.
On the therapeutics side of the business, the company is currently testing its flagship AVA6000 chemotherapy drug in clinical trials. This treatment is being developed with the group’s second chemical platform called pre|CISION. Unlike existing chemotherapy treatments, AVA6000 is highly targeted, resulting in less healthy cells being caught in the crossfire, and reducing the severity of side effects.
Frequently Asked Questions
-
Avacta was listed on the London Stock Exchange Alternative Investment Market in October 2003 through a reverse takeover. The split-adjusted floating price was 5,250p.
-
No. According to the 2020 annual report, Avacta does not pay dividends to shareholders, nor has it proposed to do so in the future.
Avacta Group Plc (LSE: AVCT) Latest News

Investing Articles
Down 65% in 2024, but can the Avacta (AVCT) share price ever recover?

Investing Articles
Is Avacta the best ex-penny stock to buy today?

Investing Articles
Down 63% in 2024, what’s going on with the Avacta (AVCT) share price?

Investing Articles
If I’d invested £1,000 in Avacta shares 5 years ago, here’s how much I’d have now

Investing Articles
Avacta shares quadrupled in five years! Am I too late to buy?

Investing Articles
Is the Avacta share price dip a buying opportunity?

Investing Articles
Is the Avacta share price about to rocket in 2023?

Investing Articles
Can the Avacta share price make me rich?

Investing Articles
Up 173%, can Avacta shares continue this incredible run?
